You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCalcium Acetate
Accession NumberDB00258  (APRD00839)
TypeSmall Molecule
GroupsApproved
Description

The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]

Structure
Thumb
Synonyms
SynonymLanguageCode
Acetate OF limeNot AvailableNot Available
Brown acetate of limeNot AvailableNot Available
Ca(oac)2Not AvailableNot Available
calcium ethanoateNot AvailableNot Available
calcium(II) acetateNot AvailableNot Available
Gray acetate of limeNot AvailableNot Available
Lime acetateNot AvailableNot Available
Lime pyroligniteNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetatecapsule667 mgoralSandoz Inc2012-03-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralSandoz Inc2012-03-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Phoslocapsule667 mgoralFresenius Medical Care North America2001-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Phoslyrasolution667 mg/5mLoralFresenius Medical Care North America2011-04-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralState of Florida DOH Central Pharmacy2014-01-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Phoslocapsule667 mgoralPhysicians Total Care, Inc.2010-03-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Phoslocapsule667 mgoralCardinal Health2001-04-02Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralClinical Solutions Wholesale2012-03-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Acetatecapsule667 mgoralRoxane Laboratories, Inc2008-02-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eliphostablet667 mgoralKAISER FOUNDATION HOSPITALS2011-08-24Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatetablet667 mgoralPaddock Laboratories, LLC2011-09-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2008-02-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralAtlantic Biologicals Corps2008-02-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralCamber Pharmaceuticals, Inc.2014-02-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatetablet667 mgoralCamber Pharmaceuticals, Inc.2014-02-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatetablet667 mgoralSafecor Health, LLC2014-08-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralREMEDYREPACK INC.2010-11-11Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralState of Florida DOH Central Pharmacy2009-07-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralState of Florida DOH Central Pharmacy2014-11-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralCardinal Health2008-02-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralCardinal Health2013-07-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eliphostablet667 mgoralHawthorn Pharmaceutical, Inc.2009-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralAmneal Pharmaceuticals of New York, LLC2014-10-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralAmerican Health Packaging2013-07-26Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralAmerican Health Packaging2012-08-27Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Eliphostablet667 mgoralCarilion Materials Management2009-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatetablet667 mgoralZydus Pharmaceuticals USA Inc.2012-02-23Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralMc Kesson Contract Packaging2013-04-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Calcium Acetatecapsule667 mgoralExelan Pharmaceuticals, Inc.2014-04-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
TeltozanNot Available
Brand mixtures
Brand NameIngredients
Anti StressCalcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium (Potassium Bicarbonate) + Pyridoxine Hydrochloride + Sodium Acetate + Sodium Chloride + Vitamin a + Vitamin B12 + Vitamin C + Vitamin D3 + Vitamin E
Electrolyte BoosterBiotin + Calcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Bicarbonate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Ascorbic Acid) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)
Electrolytes PlusCalcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3 + Vitamin E
ElectroviteCalcium Acetate + Calcium Chloride + Folic Acid + Magnesium Acetate + Menadione Sodium Bisulfite + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E
HyperlyteMulti-Electrolyte Concentrate) (Calcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate
JugelectCalcium Acetate + Calcium Citrate + Magnesium Acetate + Magnesium Citrate + Potassium Chloride + Sodium Chloride
LypholyteCalcium Acetate + Magnesium Acetate + Potassium Acetate + Potassium Chloride + Sodium Acetate + Sodium Gluconate
Medi-Kool PakAluminum Sulfate + Arnica + Boric Acid + Calcium Acetate + Camphor + Menthol + Methyl Salicylate + Tannic Acid
Mineralytes PlusCalcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Dl-Alpha Tocopheryl Acetate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a Acetate + Vitamin B12 + Vitamin B2 + Vitamin D3
Parvit IICalcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite (Vitamin K3) + Potassium (Potassium Bicarbonate) + Sodium (Sodium Acetate, Sodium Diacetate, Sodium Chloride) + Vitamin a + Vitamin B12 + Vitamin B6 (Pyridoxine Hydrochloride) + Vitamin C (Vitamin C) + Vitamin D3 + Vitamin E
RenodoronCalcium Acetate + Silicon Dioxide
Super ElectrolyteCalcium Acetate + Calcium D-Pantothenate + Choline Bitartrate + Folic Acid + Magnesium Chloride + Menadione (Menadione Sodium Bisulfite) + Nicotinamide + Potassium Chloride + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a (Vitamin a Acetate) + Vitamin B12 + Vitamin B2 (Riboflavin) + Vitamin D3 (Cholecalciferol) + Vitamin E (Dl-Alpha Tocopheryl Acetate)
Tym-PlexCalcium Acetate + Calcium Sulfide Crude + Echinacea Angustifolia + Phosphoric Acid + Phosphorus
Vitadol PlusCalcium Acetate + Folic Acid + Magnesium Chloride + Menadione Sodium Bisulfite + Potassium Bicarbonate + Sodium Acetate + Sodium Chloride + Sodium Diacetate + Vitamin a + Vitamin B12 + Vitamin B6 + Vitamin C + Vitamin D3 + Vitamin E
SaltsNot Available
Categories
CAS number62-54-4
WeightAverage: 158.166
Monoisotopic: 157.989199835
Chemical FormulaC4H6CaO4
InChI KeyVSGNNIFQASZAOI-UHFFFAOYSA-L
InChI
InChI=1S/2C2H4O2.Ca/c2*1-2(3)4;/h2*1H3,(H,3,4);/q;;+2/p-2
IUPAC Name
calcium diacetate
SMILES
[Ca++].CC([O-])=O.CC([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acid derivatives
Direct ParentAcetate salts
Alternative Parents
Substituents
  • Acetate salt
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Organic zwitterion
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External Descriptors
Pharmacology
IndicationCalcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
PharmacodynamicsPatients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Mechanism of actionCalcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.
Absorption40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCalcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
Half lifeNot Available
ClearanceNot Available
ToxicityOral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.705
Blood Brain Barrier+0.9601
Caco-2 permeable-0.5258
P-glycoprotein substrateNon-substrate0.8366
P-glycoprotein inhibitor INon-inhibitor0.9806
P-glycoprotein inhibitor IINon-inhibitor0.9866
Renal organic cation transporterNon-inhibitor0.9609
CYP450 2C9 substrateNon-substrate0.8335
CYP450 2D6 substrateNon-substrate0.9164
CYP450 3A4 substrateNon-substrate0.7384
CYP450 1A2 substrateNon-inhibitor0.9381
CYP450 2C9 substrateNon-inhibitor0.9273
CYP450 2D6 substrateNon-inhibitor0.9462
CYP450 2C19 substrateNon-inhibitor0.9608
CYP450 3A4 substrateNon-inhibitor0.9627
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.985
Ames testNon AMES toxic0.9042
CarcinogenicityCarcinogens 0.5617
BiodegradationReady biodegradable0.9734
Rat acute toxicity1.8756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Non-inhibitor0.9888
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Fresenius medical care north america
  • Cypress pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral667 mg
Solutionoral667 mg/5mL
Tabletoral667 mg
Prices
Unit descriptionCostUnit
PhosLo 667 mg capsule1.05USD capsule
Phoslo 667 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States65766652001-04-032021-04-03
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point> 160 °CNot Available
Predicted Properties
PropertyValueSource
Water Solubility147.0 mg/mLALOGPS
logP0.24ALOGPS
logP-0.22ChemAxon
logS-0.03ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Alan B. Gancy, “Process of making calcium acetate deicing agents and product.” U.S. Patent US4444672, issued November, 1946.

US4444672
General ReferenceNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 40:18.19
  • 92:02.00*
PDB EntriesNot Available
FDA labelDownload (25.6 KB)
MSDSDownload (72.9 KB)
Interactions
Drug Interactions
Drug
AmlodipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
AmrinoneCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
BepridilCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
Calcium carbonateCalcium Salts may enhance the adverse/toxic effect of Calcium Acetate.
Calcium ChlorideCalcium Salts may enhance the adverse/toxic effect of Calcium Acetate.
CeftriaxoneCalcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.
DeferiproneCalcium Salts may decrease the serum concentration of Deferiprone.
DobutamineCalcium Salts may diminish the therapeutic effect of DOBUTamine.
DolutegravirCalcium Salts may decrease the serum concentration of Dolutegravir.
EltrombopagCalcium Salts may decrease the serum concentration of Eltrombopag.
EstramustineCalcium Salts may decrease the absorption of Estramustine.
FelodipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
FlunarizineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
GabapentinCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
IsradipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
LamotrigineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
LercanidipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
Magnesium SulfateCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
NicardipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
NimodipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
NisoldipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
NitrendipineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
PerhexilineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
PrenylamineCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
RisedronateCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
VerapamilCalcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.
Food InteractionsNot Available

Targets

1. Phosphate

Kind: small molecule

Organism: Human

Pharmacological action: yes

Actions: binder

Components

Name UniProt ID Details

References:

  1. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. 1989 Oct;36(4):690-5. Pubmed
  2. Nolan CR, Qunibi WY: Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients. Curr Opin Nephrol Hypertens. 2003 Jul;12(4):373-9. Pubmed
  3. Nolan CR, Qunibi WY: Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl. 2005 Jun;(95):S13-20. Pubmed
  4. Nolan CR: Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines. Kidney Int Suppl. 2005 Jul;(96):S7-14. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:08